Abstract | BACKGROUND: The present study was undertaken to investigate the effects of policosanol in older patients with type II hypercholesterolemia and more than one concomitant atherosclerotic risk factor. METHODS: RESULTS:
Policosanol significantly decreased (p < .01) the ratios of LDL-C to HDL-C (29.1%) and TC to HDL-C (28%) at study completion, although triglycerides remained unchanged. Policosanol, but not the placebo, significantly improved (p .01) cardiovascular capacity, which was assessed using the Specific Activity Scale. No serious adverse experiences occurred in policosanol patients (p < .01), compared with seven adverse experiences (7.9%) reported by placebo patients. CONCLUSIONS: This study shows that policosanol is effective, safe, and well tolerated in older hypercholesterolemic patients.
|
Authors | G Castaño, R Más, J C Fernández, J Illnait, L Fernández, E Alvarez |
Journal | The journals of gerontology. Series A, Biological sciences and medical sciences
(J Gerontol A Biol Sci Med Sci)
Vol. 56
Issue 3
Pg. M186-92
(Mar 2001)
ISSN: 1079-5006 [Print] United States |
PMID | 11253161
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anticholesteremic Agents
- Cholesterol, HDL
- Cholesterol, LDL
- Fatty Alcohols
- policosanol
- Cholesterol
|
Topics |
- Aged
- Anticholesteremic Agents
(adverse effects, therapeutic use)
- Cardiovascular System
(drug effects, physiopathology)
- Cholesterol
(blood)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Coronary Disease
(etiology)
- Fatty Alcohols
(adverse effects, therapeutic use)
- Female
- Humans
- Hypercholesterolemia
(blood, classification, drug therapy, physiopathology)
- Male
- Middle Aged
- Risk Factors
- Safety
- Treatment Outcome
|